CURx picks up a Gilead cystic fibrosis drug ready for Phase III

San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead ($GILD), planning to launch a Phase III trial on the drug to treat lung infections in cystic fibrosis patients. The drug, a combination of fosfomycin and tobramycin, is designed to fight Pseudomonas aeruginosa infection, and, after a promising Phase II in CF patients, CURx figures it has a shot at approval. This is the inlicensing company's second deal, following a $21 million deal with Ligand ($LGND) to get its hands on a seizure medication. News

Suggested Articles

An inhaled drug developed by Aridis eradicated the novel coronavirus from infected hamsters at a much lower dose than other antibody treatments.

The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in 2 million patients.

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.